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The objective of this study was to compare the health-
related quality of life (HRQOL) of long-term to short-
term high-grade glioma (HGG) survivors, determine the 
prognostic value of HRQOL for overall survival, and 
determine the effect of tumor recurrence on HRQOL 
for long-term survivors. Following baseline assess-
ment (after surgery, before radiotherapy), self-perceived 
HRQOL (using the Medical Outcomes Study Short Form 
36 [SF-36]) and brain tumor–specific symptoms (using 
the 20-item Brain Cancer Module) were assessed every 
4 months until 16 months after histological diagnosis. 
Kaplan-Meier survival analysis and the Cox propor-
tional hazards model were performed to estimate overall 
survival of patients with impaired scores on the aggre-
gated SF-36 higher-order summary scores measuring 
physical functioning on a physical component scale and 
on a mental component scale (MCS). Sixteen patients 
with a short-term survival (baseline and 4-month follow-
up) and 16 with a long-term survival (follow-up until 16 
months after diagnosis) were selected out of 68 initially 
recruited HGG patients. At baseline, the short-term and 
long-term survivors did not differ in their HRQOL. 
Between baseline and the 4-month follow-up, HRQOL 
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of short-term survivors deteriorated, whereas the long-
term survivors improved to a level comparable to healthy 
controls. Patients with impaired mental functioning 
(MCS) at baseline had a shorter median survival than 
patients with normal functioning. After accounting for 
differences in patient and tumor characteristics, how-
ever, mental functioning was not independently related 
to poorer overall survival. Not surprisingly, in the group 
of long-term survivors, the five patients with recurrence 
had a more compromised HRQOL at the 16-month fol-
low-up compared to the 11 patients without recurrence. 
We concluded that baseline HRQOL is not related to 
duration of survival and that long-term survivors show 
improvement of HRQOL to a level comparable to that of 
the healthy. Neuro-Oncology 11, 51–58, 2009 (Posted 
to Neuro-Oncology [serial online], Doc. D08-00019, 
July 10, 2008. URL http://neuro-oncology.dukejournals 
.org; DOI: 10.1215/15228517-2008-049)
Keywords: health-related quality of life, high-grade 
glioma survivors
High-grade gliomas (HGGs) are the most frequent primary brain tumors, with an annual inci-dence of 3–4 per 100,000.1 Within the group 
of HGGs, glioblastoma multiforme (GBM) is by far the 
most common and most aggressive subtype. Although 
treatment modalities have been refined over the years 
(microsurgery, radiotherapy, and concomitant chemo-
therapy), the overall prognosis in these patients remains 
Copyright 2009 by the Society for Neuro-Oncology
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dismal. While significant progress has been achieved 
with the introduction of radiotherapy plus concomi-
tant and adjuvant temozolomide for GBM patients,2 the 
prognosis of the majority of HGG patients is still pre-
dominantly correlated with nonmodifiable factors such 
as age, tumor grade, and performance status at the time 
of diagnosis.3–7
During the last decades, many studies evaluating new 
treatment protocols for cancer patients mainly focused 
on overall survival and progression-free survival (PFS) as 
primary response measures. It is increasingly recognized 
that the choice of treatment also should entail careful 
consideration of its effects on the health-related quality of 
life (HRQOL) during the remaining survival time. Con-
sidering their limited survival, this is even more urgent in 
patients with HGGs. As survival is limited, patients opti-
mally should be informed of the impact of all treatment 
options on their quality of life at the time of diagnosis. 
Relatively little is known about HRQOL during the dis-
ease course of patients with HGGs. Although one might 
intuitively expect a decrease in HRQOL in the course 
of the disease, this does not necessarily have to be the 
case. A recent European Organization for Research and 
Treatment of Cancer (EORTC) study showed that newly 
diagnosed GBM patients did not report lasting negative 
effects of tumor treatment with radiotherapy plus con-
comitant and adjuvant temozolomide on HRQOL and 
even demonstrated a slight improvement after diagnosis, 
until 6 months after they started the actual treatment.8 
The authors attributed this improvement to the limited 
number of patients with recurrent disease during the first 
6 months and speculated that the improvement could be 
the result of so-called survivorship.
Indices of HRQOL may serve as independent pre-
dictors of survival and can thus be very useful in clini-
cal practice when treatment decisions have to be made. 
Only a few studies have addressed this issue in patients 
with primary brain tumors. Sehlen and colleagues,9 
for instance, showed that HRQOL as measured by the 
FACT-G total score, and not other patient and tumor 
characteristics, was predictive of survival in a patient 
population with primary and secondary brain tumors. 
However, dissimilar results were obtained from the study 
of Mauer et al.10 who evaluated the predictive value of 
HRQOL following surgery in newly diagnosed brain 
tumor patients treated with either radiotherapy alone or 
radiotherapy and concomitant temozolomide followed 
by six adjuvant cycles of temozolomide. They found 
HRQOL to have only little predictive value in addition to 
established clinical factors such as age, performance sta-
tus, extent of surgery, corticosteroids at entry, cognitive 
status, and MGMT promotor methylation status. These 
contradictory findings appear to be mainly due to differ-
ences in statistical analyses. The aforementioned lack of 
information on the course of HRQOL during treatment, 
as well as the contradictory results from previous studies 
on the predictive value of HRQOL, clearly demonstrate 
the necessity to employ further research into the prog-
nostic value of HRQOL. In this article we describe the 
course of HRQOL of a heterogeneous cohort of patients 
with HGG. In particular, we compared initial HRQOL 
of those patients still alive at least 2 years following 
diagnosis (i.e., long-term survivors) with initial HRQOL 
of those who died within 1 year after the histological 
diagnosis (i.e., short-term survivors) and evaluated the 
HRQOL at different follow-up moments to determine 
when improvement or deterioration is to be expected in 
the course of the disease. Furthermore, we evaluated the 
prognostic value of HRQOL in this patient population 
and the differences in HRQOL between long-term sur-
vivors with and without tumor progression in the course 
of their disease.
Patients and Methods
Patients
This study is part of a large nationwide longitudinal 
study in the Netherlands into the neurocognitive status 
and HRQOL of high- and low-grade glioma patients 
and their partners. The results of these patients’ neuro-
cognitive function and HRQOL at baseline (i.e., follow-
ing surgery, prior to the start of radiotherapy) have been 
published previously.11 In short, consecutive, newly diag-
nosed, histologically confirmed patients were recruited 
from six centers in the Netherlands (listed in Acknowl-
edgments) based on the following criteria: (1) had WHO 
grade III astrocytoma, oligodendroglioma. or oligoastro-
cytoma, or WHO grade IV glioma (GBM); (2) had an 
estimated life expectancy of at least 3 months; (3) were 
eligible for radiotherapy; and (4) were able to commu-
nicate in the Dutch language. The institutional review 
boards of all participating hospitals approved the study 
protocol. Patients were asked to participate by their 
treating physician (i.e., neurologist, neurosurgeon, medi-
cal oncologist, or radiation oncologist), and informed 
consent was obtained. Medical charts were reviewed to 
obtain data on patient, tumor, and treatment character-
istics. Patients were asked to fill out the questionnaires 
listed below, at baseline and every 4 months thereafter 
until 16 months after histological diagnosis.
Outcome Measures
Health-related quality of life. The Medical Outcomes 
Study Short Form 36 (SF-36) is a self-report question-
naire composed of 36 items, organized into eight multi-
item scales assessing physical functioning (PF), role 
limitations caused by physical functioning (RP), bodily 
pain (BP), general health perceptions (GH), vitality 
(VT), social functioning (SF), role limitations caused 
by emotional problems (RE), and general mental health 
(MH). Raw scores were converted linearly to 0–100 
scale scores, with higher scores indicating better func-
tioning.12 In addition to individual SF-36 scale scores, 
higher-order component scores were calculated on two 
scales: a physical component scale (PCS) and a mental 
component scale (MCS).
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scores above or beneath the median score of the whole 
group of 68 patients accounting for age, tumor grade, 
extent of surgery, tumor lateralization, and performance 
status on the other.
To gauge the influence of tumor recurrence on 
HRQOL at 16-month follow-up, the long-term survi-
vors were stratified by the presence or absence of tumor 
recurrence during their follow-up. Subsequently, non-
parametric Mann-Whitney U tests were used to test for 
differences between the two patient groups. All statisti-
cal analyses employed were two-tailed with alpha set 
at 0.05.
Results
Patient Characteristics
Eighteen of the 90 eligible HGG patients declined to par-
ticipate because they expected the study to be too stress-
ful, and four patients were excluded because of severe 
aphasia. Consequently, 68 HGG patients were included 
in the study. Of these 68 patients, 16 died within 1 year 
after histological diagnosis (i.e., short-term survivors) and 
16 were still alive 2 years after the histological diagno-
sis (i.e., long-term survivors). The other 36 patients died 
between 1 and 2 years after diagnosis. Table 1 shows the 
characteristics of these patients stratified by survival. As 
expected, long-term survivors were significantly younger 
(p 5 0.001) and more often had less malignant (WHO 
grade III) tumors (p 5 0.000). However, the functional 
status at baseline (i.e., KPS scores) did not vary between 
the long- and short-term survivors.
Since only three short-term survivors had a follow-up 
at 8 months, we decided to evaluate baseline and 4-month 
follow-up. All long-term survivors had a follow-up 
until 16 months after the histological diagnosis. Dur-
ing follow-up, 5 of the 16 long-term survivors were con-
fronted with tumor recurrence.
Brain tumor–specific symptoms. Brain tumor–specific 
symptoms were assessed by means of a questionnaire (20-
item Brain Cancer Module [BCM-20]).13 The BCM-20 
contains five multi-item scales consisting of future uncer-
tainty, visual disorder, motor dysfunction, communi-
cation deficit, and emotional distress. It also contains 
seven single items (headache, seizures, drowsiness, hair 
loss, itching, weakness of legs, and difficulties with blad-
der control). In this study we did not include the emo-
tional distress item because of the overlap with the SF-36 
mental health scale. We also did not include hair loss, 
itching, and bladder control. Raw scores of the BCM-
20 were linearly converted to 0–100 scale scores, with 
higher scores representing lower levels of functioning.
Statistical analysis. Short-term survivors were defined 
as those patients out of the 68 HGG patients initially 
included who had a baseline and 4-month follow-up 
assessment and who died within 1 year following the 
histological diagnosis. Following baseline, long-term 
survivors had a follow-up at 4, 8, 12, and 16 months 
and survived for over 2 years. Pearson’s chi-square test 
or analysis of covariance (ANCOVA), correcting for 
differences in age, sex, and marital status, was used 
to test for differences between patient groups in their 
self-perceived HRQOL. The nonparametric Wilcoxon 
signed-rank test was used to test for significance of 
potential changes in HRQOL of HGG patients between 
baseline and the subsequent follow-ups.
For the analysis of the predictive value of baseline 
HRQOL scores on overall survival, we analyzed data of 
all 68 patients of whom baseline performance has been 
reported elsewhere.11 Kaplan-Meier analysis was per-
formed to obtain estimates of overall survival of patients 
with an impaired score on the SF-36 PCS and MCS dis-
regarding differences in tumor, treatment, or patient 
characteristics. Subsequently, the Cox proportional haz-
ards model was used to assess the associations between 
overall survival on the one hand and MCS and PCS 
Table 1. Patient characteristics at baseline of short-term (deceased within 1 year after histological diagnosis) and long-term survivors (still 
alive 2 years after histological diagnosis) 
 Short-Term Survivors Long-Term Survivors 
 (n = 16) (n = 16) p Value
Age ± SD (years) 56.4 ± 11.8 40.9 ± 13.2 0.001
Sex: male/female (%) 100/0 75/25 0.033
Marital status: married/unmarried (%) 100/0 50/50 0.001
education: mean/SD 4.1/1.7 4.3/2.0 0.179
Tumor grade: III/IV (%) 0/100 62.5/37.5 0.000
Tumor lateralization: left/right/bilateral (%) 31.3/68.7/0 50/50/0 0.280
Neurosurgery: biopsy/resection (%) 0/100 6.3/93.7 0.310
Total dose radiotherapy (Gy): mean/range/SD 49/28–64/10.8 57/42–66/7.5 0.210
Number of fractions radiotherapy: mean/range/SD 20/4–32/9.6 28/12–33/7.1 0.032
KPS: mean/range 80/50–100 80/60–100 0.616
Antiepileptic drug use: yes/no/unknown (%) 75/18.8/6.2 68.8/31.3/0 0.462
Dexamethasone use: yes/no/unknown (%) 31.2/43.8/25 25/75/0 0.066
Survival (months): mean/range/SD 9.8/5–12/2.4 38.3/27–59/11.7 0.000
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At baseline, 23 of 32 survivors were on mono- or 
polytherapy with the older antiepileptic drugs such as 
valproic acid, carbamazepine, and phenytoin. Between 
baseline and 4-month follow-up, the short-term sur-
vivors only received radiotherapy. During follow-up, 
however, 7 of the 16 sixteen long-term survivors received 
subsequent antitumor treatment after the initial radio-
therapy. Three of the 11 patients without tumor pro-
gression during follow-up received treatment. One 
patient received six cycles of PCV (procarbazine, CCNU 
[lomustine], and vincristine) in the adjuvant setting, one 
patient underwent stereotactic radiotherapy 3 months 
after the initial conventional radiotherapy, and a third 
patient received dibromodulocitol and BCNU (carmus-
tine) as part of a trial.
Four of the five long-term survivor patients with 
tumor progression during follow-up received treatment: 
two patients were subsequently treated with four cycles 
of PCV, and one of these two patients again underwent 
radiotherapy (13 3 3 Gy). One patient received two 
cycles of PCV and the fourth patient received stereo-
tactic radiotherapy (1 3 15 Gy). 
HRQOL of Short-Term and Long-Term Survivors
Mean SF-36 scores of short-term survivors at baseline 
and 4-month follow-up are displayed in Table 2. Mean 
SF-36 scores of long-term survivors at baseline and 4-, 
8-, 12-, and 16-month follow-ups are displayed in Table 
3. During the course of their disease, the short-term 
survivors developed more general health problems (Wil-
coxon; p 5 0.015), while HRQOL in the other domains 
remained unaffected. The long-term survivors, on the 
other hand, experienced improvement in physical, social, 
and emotional functioning in the course of their disease. 
These improvements were also reflected in the physical 
higher-order component scales (PCS) in long-term sur-
Table 2. Sf-36 scores of short-term survivors at baseline and 
4-month follow-up
 Baseline 4-month Follow-up p Valuea
Scale Mean (SD) Mean (SD)
Pf 63.1 (28.6) 53.9 (32.4) NS
RP 14.1 (24.1) 21.7 (38.8) NS
BP 65.4 (28.9) 78.6 (20.4) NS
GH 56.5 (19.2) 39.7 (17.2) 0.015
VT 59.0 (20.0) 47.8 (21.9) NS
Sf 67.2 (25.0) 70.0 (31.6) NS
Re 48.9 (45.2) 42.2 (42.7) NS
MH 67.8 (19.4) 63.5 (21.5) NS
Abbreviations: Sf-36, Medical Outcomes Study Short form 36; Pf, physical 
functioning; NS, not significant; RP, role physical; BP, bodily pain; GH, general health; 
VT, vitality; Sf, social functioning; Re, role emotional; MH, mental health.
aNonparametric (Wilcoxon).
Table 3. Sf-36 scores of long-term survivors at baseline and 4-, 8-, 12-, and 16-month follow-up
 Baseline  4-Month 8-Month 12-Month 16-Month 
  Mean  Follow-up Follow-up Follow-up Follow-up 
Scale  (SD)  Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Pf 65.2 (24.1) 79.4a (18.5) 75.9 (24.1) 82.3b (20.1) 78.8c (20.7)
RP 21.9 (35.2) 46.4 (40.3) 54.7d (45.8) 67.9e (42.1) 61.0f (43.8)
BP 57.3 (25.8) 87.2g (16.4) 85.9h (20.0) 90.9i (12.6) 81.3j (24.2)
GH 53.4 (18.1) 59.4 (18.6) 58.9 (20.3) 62.3 (18.6) 55.3 (19.1)
VT 57.5 (21.4) 58.2 (24.6) 66.0 (20.8) 68.6 (13.4) 65.3 (19.1)
Sf 55.5 (33.8) 75.9 (22.7) 76.6k (27.7) 80.8l (18.2) 82.8m (17.0)
Re 62.5 (40.1) 76.2 (33.2) 75.0 (41.3) 92.9n (26.7) 87.5 (34.2)
MH 73.5 (12.0) 73.1 (18.5) 79.8 (16.3) 80.9 (22.7) 78.0 (13.8)
Abbreviations: Sf-36, Medical Outcomes Study Short form 36; Pf, physical functioning; RP, role physical; BP, bodily pain; GH, general health; 
VT, vitality; Sf, social functioning; Re, role emotional; MH, mental health.
aImprovement in physical functioning between baseline and 4-month follow-up (nonparametric Wilcoxon; p = 0.036).
bImprovement in physical functioning between baseline and 12-month follow-up (p = 0.017).
cImprovement in physical functioning between baseline and 16-month follow-up (p = 0.012).
dImprovement in physical role between baseline and 8-month follow-up (p = 0.012).
eImprovement in physical role between baseline and 12-month follow-up (p = 0.007).
fImprovement in physical role between baseline and 16-month follow-up (p = 0.027).
gImprovement in complaints of bodily pain between baseline and 4-month follow-up (p = 0.010).
hImprovement in complaints of bodily pain between baseline and 8-month follow-up (p = 0.002).
iImprovement in complaints of bodily pain between baseline and 12-month follow-up (p = 0.017).
jImprovement in complaints of bodily pain between baseline and 16-month follow-up (p = 0.027).
kImprovement in social functioning between baseline and 8-month follow-up (p = 0.029).
lImprovement in social functioning between baseline and 12-month follow-up (p = 0.029).
mImprovement in social functioning between baseline and 16-month follow-up (p = 0.007).
nImprovement in emotional role between baseline and 12-month follow-up (p = 0.005).
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vivors. The scores on the PCS and MCS of the long-term 
survivors are displayed in Fig. 1.
Comparison of the HRQOL of the long- and short-
term survivors (see Fig. 2) showed that long-term survi-
vors reported fewer general health problems (ANCOVA; 
p 5 0.027) at 4-month follow-up than did short-term 
survivors. Comparison of the two higher-order com-
ponent scores showed a significantly lower PCS in the 
short-term survivors at 4-month follow-up (ANCOVA; 
p 5 0.034) when compared to the long-term survivors. 
No significant differences were found in mental func-
tioning as expressed by the MCS.
Brain Tumor– and Treatment-Specific Symptoms of 
Short-Term and Long-Term Survivors
Table 4 reports the mean scores for the single items of 
the BCM-20 in short-term survivors. Between baseline 
and 4-month follow-up, short-term survivors showed an 
increased weakness of legs (Wilcoxon; p 5 0.026). Symp-
toms of long-term survivors did not change within this 
time frame (Table 5). Comparison of the BCM-20 of the 
long- and short-term survivors showed that long-term 
survivors reported less weakness of legs (ANCOVA; p 
5 0.027) at the 4-month follow-up when compared to 
short-term survivors. Table 5 reports the mean scores for 
the single items of the BCM-20 in long-term survivors. 
Symptoms in these patients were relatively stable over 
time. The long-term survivors suffered significantly less 
from future uncertainty at the 8-, 12-, and 16-month 
follow-ups compared to their baseline evaluation (Wil-
coxon; p 5 0.041, p 5 0.010, and p 5 0.002, respec-
fig. 1. Mean physical component scale (PCS) and mental com-
ponent scale (MCS) scores of long-term survivors at the different 
follow-up moments. (1 = baseline; 2 = 4-month; 3 = 8-month; 4 = 
12-month; 5 = 16-month).
fig. 2. Medical Outcomes Study Short form 36 (Sf-36) scores of 
short- and long-term survivors at baseline (A) and Sf-36 scores 
of the short- and long-term survivors at 4-month follow-up (B). 
Abbreviations: Pf, physical functioning; RP, role physical; BP, bodily 
pain; GH, general health; VT, vitality; Sf, social functioning; Re, 
role emotional; MH, mental health.
Table 4. Mean scores of the single items of the BCM-20 of short-term survivors 
  4-Month  
 Baseline  Follow-up  p Valuea  
Symptom Mean (SD) Mean (SD) Mean
future uncertainty 51.4 (26.9) 51.1 (28.0) NS
Visual disorder 20.8 (20.2) 15.6 (12.5) NS
Motor dysfunction  19.4 (20.1) 33.0 (34.8) NS
Communication deficit 20.1 (30.4) 25.2 (32.1) NS
Headache  35.4 (37.5) 24.4 (29.5) NS
Seizures 12.5 (26.9) 26.7 (31.4) NS
Drowsiness 22.9 (23.5) 26.2 (23.3) NS
Leg weakness 12.5 (20.6) 35.6 (32.0) 0.026
Abbreviations: BCM-20, 20-item Brain Cancer Module; NS, not significant. 
aNonparametric (Wilcoxon).
A
B
 at Vrije Universiteit - Library on July 19, 2011
n
e
u
ro
-o
n
cology.oxfordjournals.org
D
ow
nloaded from
 
Bosma et al.: Health-related quality of life in high-grade glioma patients
56   Neuro-oNcology • f e B R U A R y  2 0 0 9
tively). Furthermore, the long-term survivors also had 
fewer headaches and less weakness of legs at 12-month 
follow-up compared to the baseline assessment (Wil-
coxon; p 5 0.047 and p 5 0.046, respectively).
Prognostic Value of Baseline HRQOL on Survival
Of the 68 patients included in the study, 62 had died at 
the time of statistical analysis; thus, data of six patients 
were censored. Kaplan-Meier analysis yielded significant 
differences in the median survival between patients with 
a baseline MCS score lower than the median (median 
MCS score 5 45, n 5 31), and those patients with a MCS 
score higher than median at baseline (n 5 31). Patients 
with a low MCS score at baseline had a significantly 
shorter median survival (8 months) than those with a 
high MCS score (14.5 months; log rank test: p 5 0.023) 
as shown in Fig. 3.
However, a multivariate Cox proportional hazards 
model of survival time, including score on the MCS, age, 
sex, tumor grade, tumor treatment, and KPS, showed 
that baseline MCS score did not significantly add prog-
nostic value to the model including these patient and 
tumor characteristics.
Influence of Tumor Recurrence on HRQOL and 
Symptoms in Long-Term Survivors
Because we expected tumor recurrence to influence the 
HRQOL and brain tumor–specific symptoms in long-
term survivors, we evaluated the HRQOL and brain 
tumor–specific symptoms of the 16 long-term survi-
vors at the 16-month follow-up. Five of the 16 patients 
suffered from tumor recurrence during follow-up: two 
patients at 4 months (one of them was subsequently 
treated with four cycles of PCV, and one patient again 
underwent radiotherapy [13 3 3 Gy]). At 8-month 
follow-up another two patients demonstrated tumor 
recurrence (one patient received two cycles of PCV, and 
one patient received no treatment), and one more patient 
suffered from tumor recurrence between the 12- and 
16-month follow-ups and received stereotactic radio-
therapy (1 3 15 Gy).
Patients with tumor recurrence during follow-up 
evidently had more problems with physical functioning 
(Mann-Whitney U; p 5 0.000), with work or other daily 
activities resulting from physical health limitations (p 5 
0.003), mental health (p 5 0.027), and general health 
(p 5 0.019) at 16-month follow-up than those without 
recurrence. The increase in physical complaints was also 
reflected in the higher-order physical component scale 
(PCS; p 5 0.003). Long-term survivors without tumor 
recurrence experienced significantly less motor dysfunc-
Table 5. Mean scores of the single items of the BCM-20 of long-term survivors 
 Baseline  4-Month 8-Month 12-Month 16-Month 
  Mean  Follow-up Follow-up Follow-up Follow-up 
Symptom  (SD)  Mean (SD) Mean (SD) Mean (SD) Mean (SD)
future uncertainty 43.8 (30.5) 31.6 (28.0) 25.0a (20.4) 22.0b (23.1) 19.1c (17.8)
Visual disorder 12.5 (14.6) 18.3 (23.3) 11.1 (14.1) 10.4 (18.5) 12.2 (15.2)
Motor dysfunction  15.3 (14.0) 8.7 (13.2) 14.6 (17.1) 10.7 (15.8) 15.3 (17.2)
Communication deficit 20.8 (16.2) 18.3 (19.8) 18.8 (20.2) 23.7 (21.8) 22.2 (23.0)
Headache  31.3 (33.3) 11.9 (16.6) 18.8 (24.3) 8.9d (15.3) 16.7 (21.1)
Seizures 8.3 (14.9) 14.2 (21.5) 10.4 (20.1) 4.4 (11.7) 16.7 (29.8)
Drowsiness 15.6 (21.3) 19.1 (31.3) 10.4 (20.1) 13.3 (21.8) 10.4 (23.5)
Leg weakness 8.3 (15.0) 0 (0) 6.3 (18.1) 0e (0) 14.6 (29.7)
Abbreviation: BCM-20, 20-item Brain Cancer Module. 
aSignificant improvement between baseline and 4-month follow-up (nonparametric Wilcoxon; p = 0.041).
bImprovement in future uncertainty between baseline and 12-month follow-up (p = 0.010).
cImprovement in future uncertainty between baseline and 16-month follow-up (p = 0.002).
dImprovement in headache complaint between baseline and 12-month follow-up (p = 0.047).
eImprovement in leg weakness between baseline and 12-month follow-up (p = 0.046).
fig. 3. Kaplan-Meier survival curves of patient groups stratified by 
the mental component scale (MCS) score at baseline.
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tion (Mann-Whitney U; p 5 0.002), weakness of legs 
(p 5 0.009), visual disorders (p 5 0.013), and future 
uncertainty (p 5 0.027) than long-term survivors with 
tumor recurrence.
Discussion
In this study we evaluated both HRQOL and brain 
tumor–specific symptoms among HGG patients in the 
course of their disease. Our primary objective was to 
investigate whether long- and short-term survivors of 
high-grade gliomas were characterized by different 
HRQOL and symptom patterns. Our second goal was 
to evaluate the prognostic value of baseline HRQOL on 
overall survival, and our third goal was to determine 
whether the HRQOL of long-term survivors with tumor 
recurrence during our follow-up differs from HRQOL of 
patients without recurrence during follow-up.
Following surgery, and prior to radiotherapy, long-
term and short-term survivors did not differ in HRQOL. 
From baseline until the 4-month follow-up, however, 
short-term survivors reported a more compromised 
HRQOL. In contrast with short-term survivors, the 
long-term survivor group showed improvements in 
HRQOL during the course of their disease with further 
improvement in physical functioning at each consecu-
tive follow-up moment. Most surprising, physical func-
tioning of these long-term survivors as expressed by 
PCS scores even reached levels comparable to that of a 
healthy control population.14
The physical improvements observed in the long-
term survivors during the first months after inclusion 
can be attributed to the recuperation from the surgery 
and radiotherapy, but this factor cannot fully explain 
the subsequent improvements in later stages of the dis-
ease. The long-term survivors, although confronted with 
a brain tumor with an expected poor prognosis, com-
plained less about future uncertainty between the 8- and 
16-month follow-up, which might be attributed to the 
fact that patients at that time realize that they are func-
tioning relatively well after surgery and radiotherapy 
(the so-called “survivorship” feeling).
Salander and colleagues15 interviewed 30 patients con-
fronted with the diagnosis of a malignant brain tumor. 
They showed that most patients were aware of the fact 
that the tumor exposed them to grave danger, but that 
they were able to use various cognitive maneuvers at the 
same time to create protection and hope. Another expla-
nation for the counterintuitive findings relates to the so-
called response shift. An adaptive psychological process 
may account for the poor correlation between disease 
severity, treatment burden, and prognosis on the one 
hand, and the HRQOL appraisal on the other. It is pos-
sible that patients may progressively narrow their focus 
on the pursuit of certain goals, while disengaging from 
others. It is then possible to maintain a stable appraisal 
of the HRQOL by adjusting what they consider to be 
relevant to it.16,17 This may have been the case in the 
long-term survivors in our study.
In our study, mental functioning as measured by the 
MCS did not have value in predicting overall survival in 
addition to age, tumor grade, extent of surgery, tumor 
lateralization, and performance status. Our results cor-
roborate those of Mauer et al.,10 who showed that the 
HRQOL and tumor-related symptoms, as measured 
through the 30-question EORTC Quality of Life Ques-
tionnaire (EORTC-QLQ-C30) and BCM-20, added 
relatively little to clinical factors that predict survival in 
newly diagnosed glioblastoma patients. Our data concur 
with those of Sehlen et al.,9 who showed that the FACT-G 
total score was an independent predictor of survival in 
patients with primary and secondary brain tumors. The 
differences between these studies could be induced by 
differences in patient population (Sehlen et al. evalu-
ated both patients with a primary and secondary brain 
tumor, whereas Mauer et al. and we evaluated only 
patients with a high-grade primary brain tumor).
The long-term survivor group consisted of patients 
who suffered from tumor recurrence during the study 
and patients in whom the tumor recurred after the 
follow-up period. As expected, comparison of these 
two groups showed that the patients with recurrence 
had a more compromised functioning as expressed by 
PCS scores and complained more of motor dysfunction, 
weakness of legs, visual disorders, and future uncer-
tainty. Giovagnoli et al.18 also showed that the global 
quality of life was more compromised in a group of 
patients with tumor recurrence at various time points 
compared to patients with stable disease. They showed 
that HRQOL was determined by multiple factors. In 
these patients, psychosocial factors were the strongest 
determinants of the HRQOL.18,19
The lack of difference in the score on the MCS 
between patients with and without tumor recurrence 
in our study suggests that patients were mentally stable 
despite the fact that they suffered from tumor recurrence 
and despite their physical problems. It is possible that 
this effect is a result of the aforementioned survivorship 
feeling and/or response shift.
Evidently, this study has its limitations. First of all, 
the patient group is rather small. To compare the long-
term with short-term survivors, we were able to select 
32 out of 68 HGG patients. Second, patients were 
included before the introduction of the combined treat-
ment modality (radiotherapy with concomitant chemo-
therapy followed by six cycles of adjuvant temozolo-
mide) for glioblastoma patients. However, we included 
not only glioblastoma, but also WHO grade III tumors, 
whose standard postoperative treatment nowadays still 
consists of radiotherapy. More important, only 37% of 
the population in this study were glioblastoma patients. 
Third, during follow-up, 7 of the 16 long-term survi-
vors received subsequent antitumor treatment after 
the initial radiotherapy. Three of the 11 patients with-
out tumor progression during follow-up received adju-
vant treatment. Due to the small sample size and the 
variety of adjuvant antitumor treatment, no post hoc 
analysis was done stratifying for the different antitumor 
treatments.
In conclusion, long-term survivors show improve-
ment in HRQOL during the course of their disease and 
even attain levels that are comparable to that of healthy 
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controls, whereas short-term survivors start at a lower 
level and hardly show improvement. Furthermore, 
although better mental functioning following surgery 
predicts longer survival, it does not independently add 
to the predictive value of established patient and tumor 
characteristics. In the long-term survivor group, tumor 
recurrence interfered with HRQOL, particularly with 
physical problems and feelings of future uncertainty.
From this study we conclude that those patients with 
a long-term survival can have a good quality of life after 
the histological diagnosis, which is an important issue 
for both patient and caregiver and for the treating physi-
cian who has to consider treatment decisions carefully 
during the remaining survival time.
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